Treatment of wild-type gastrointestinal stromal tumor (WT-GIST) with imatinib and sunitinib

Pediatr Blood Cancer. 2008 Feb;50(2):386-8. doi: 10.1002/pbc.21312.

Abstract

We report a rare case of advanced, metastatic gastrointestinal stromal tumor (GIST) in a young female. Molecular analysis of the tumor revealed wild-type (WT) KIT and platelet derived growth factor receptor alpha (PDGFRA) gene status with no mutations characteristic of adult GIST. Despite this she had clinical benefit and evidence of radiological response to sequential treatment with the tyrosine kinase inhibitors imatinib and sunitinib.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Benzamides
  • Female
  • Gastrointestinal Stromal Tumors / drug therapy*
  • Gastrointestinal Stromal Tumors / genetics
  • Humans
  • Imatinib Mesylate
  • Indoles / administration & dosage
  • Piperazines / administration & dosage
  • Proto-Oncogene Proteins c-kit / genetics
  • Pyrimidines / administration & dosage
  • Pyrroles / administration & dosage
  • Receptor, Platelet-Derived Growth Factor alpha / genetics
  • Sunitinib

Substances

  • Benzamides
  • Indoles
  • Piperazines
  • Pyrimidines
  • Pyrroles
  • Imatinib Mesylate
  • Proto-Oncogene Proteins c-kit
  • Receptor, Platelet-Derived Growth Factor alpha
  • Sunitinib